Su'iga filifilia ma fa'aigoa fa'aigoa fa'amalama o N-terminal glycine-containing peptides: meafaigaluega fou e faʻamalamalamaina suʻesuʻega faasaienisi o le olaga

Su'iga filifilia ma fa'aigoa fa'aigoa fa'amalama o N-terminal glycine-containing peptides: meafaigaluega fou e faʻamalamalamaina suʻesuʻega faasaienisi o le olaga


Peptides o ni tagata taua i gaioiga o le olaga, ma o latou suiga patino ma fa'ailoga e taua mo le su'esu'eina o latou fausaga ma galuega. Over the past decade, methods have been developed to label glycine on α-carbon. Peitai, these methods require pre-functionalization of glycine, which is not possible for rapid recognition of natural amino acids.In this study, we report the dual activation of the α-methylene of glycine, which distinguishes this glycine from 19 other amino acids.

Technical Advantages

Specific selectivity, utilizing the unique chemical properties of N-terminal glycine to realize its specific reaction with modifying reagents and avoid the interference of other amino acid residues.

  • Universal: Applicable to a wide range of N-terminal glycine-containing peptides, as well as different modification groups and fluorescent dyes.
  • Wide range of applications: Provide a powerful tool for peptide structure and function studies, drug screening, bio-imaging and other fields.


This study provides a method for selective labeling of N-terminal glycine peptides using 1,3-diphenyl 1,3-diones to provide pyrrole-based fluorescent products. It is strictly selective for N-terminal glycine due to the “dual activation” mechanism. It provides a theoretical basis for customized N-glycine-based fluorescence modification and a stability test method for rapid identification of N-terminal glycine-containing peptides.

admin Avatar

Bingyan Gao

Quality and Analytical Technician Tomai Autu: Separation and identification of trace impurities, HPLC/MS method development, chiral purity analysis, and compliance with international pharmacopoeias.

Tala'aga: Bingyan Gao is the “ultimate gatekeeper” of peptide purity and quality. He is proficient in the use of various high-end analytical instruments and specializes in developing customized chromatographic separation methods for highly complex modified peptides. He has established a rigorous impurity profiling system that not only ensures product purity of 99% or higher but also precisely identifies and eliminates trace impurities that could cause immunogenicity. With a deep understanding of FDA and EMA regulatory requirements for peptide drugs, he ensures that every batch released from the facility is accompanied by a comprehensive and authoritative Certificate of Analysis (COA).

Su'esu'eina Mea Moni & Fa'atonu Taiala
Toe iloilo e: Mataupu Faavae Tomai
Faasoa atu lenei tala
Aiga Saili Whatsapp Au'aunaga Oloa